Anti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogram

07 Jul 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Background. Thrombocytopenia is a frequent complication of human immunodeficiency virus (HIV) infection, tire arising through diverse mechanisms including autoimmune platelet destruction, advanced immunodeficiency, and systemic comorbidities.
Distinguishing thrombocytopenia driven primarily by autoimmune platelet destruction from that related to advanced immunodeficiency remains a clinical challenge, as current standard markers often fail to stratify these distinct pathophysiological phenotypes. Methods.
We conducted a case-control study enrolling 196 HIV-infected individuals (98 thrombocytopenia cases, 98 controls) to develop a clinical prediction model for HIV-associated thrombocytopenia. Candidate predictors were identified through univariable analysis, and AIC-based backward stepwise logistic regression was used to construct a parsimonious multivariable model.
A nomogram was generated for bedside risk stratification, and dose-response analysis examined CD4+ T-cell counts and anti-platelet autoimmunity.

Clinical Editorial

Frontiers in Immunology published a clinical update in Infectious Disease on 07 Jul 2026.

The item focuses on Anti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogram.

Review the original article for the full source wording and details.